CClinicalTrials.gg
TerminatedNCT00185016Updated Sep 16, 2005

Women Abuse and the Role of the Family Doctor.

An interventional study of a training to improve recognition of partner abuse. in Improved Recognition of Partner Abuse, Gender Differences in Discussing Partner Abuse and Abused Women's Expectations,Experiences, sponsored by Radboud University Medical Center. Terminated at 1 site in Netherlands. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-09-16.

Sponsored by Radboud University Medical Center · Not applicable, Interventional, and Educational/counseling/training

Phase
Not applicable
Study type
Interventional
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The study tested a training to improve recognition of abused female patients in family practice.Effect measures of the training were: number of reported cases wherein the doctor suspected and discussed partner abuse and the number of non-obviuos reasons to suspect partner abuse.We assumed that following a training would improve the recognition of abused women.

Secondary to this trial we explored gender differences of family doctors in discussing partner abuse and we interviewed women recently identified by their family doctor. Medical histories of recently identified abused women were studied to assess health problems and health-care utilisation.

02

Conditions studied

  • Improved Recognition of Partner Abuse
  • Gender Differences in Discussing Partner Abuse
  • Abused Women's Expectations,Experiences
  • Abused Women's Health Care Utilisation

Keywords

  • intimate partner abuse
  • gender
  • education
  • attitude
  • family doctor
  • health care utilisation
  • abused women
03

In context

Lead sponsor

Radboud University Medical Center is the lead sponsor of 959 studies on the registry; 134 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female

Eligibility criteria

Inclusion Criteria:women consulting in family practice, age 18 years and older -

Exclusion Criteria:we excluded only for the interviews: women who were assessed by their family doctor to be in danger because of the abusive situation, women with a psychiatric condition.

-

05

Study design

Phase
Not applicable
Primary purpose
Educational/counseling/training
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single

Interventions

  • Behaviorala training to improve recognition of partner abuse.
06

What researchers measure

Primary outcomes

  1. number of reported cases wherein a doctor suspected and discussed partner abuse.

Secondary outcomes

  1. number of cases with non-obvious symptoms wherein a doctor suspected partner abuse.

07

Study locations

1 site
  • Radboud University Medical Centre
    Nijmegen, 6500 HB, Netherlands
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 16, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00185016
Lead sponsor
Radboud University Medical Center
Collaborators
Theia Foundation, Zilveren Kruis Achmea
First posted
Sep 16, 2005
Start date
Mar 2003
Completion
Nov 2004
Last update
Sep 16, 2005

Study contacts

Toine LM Lagro-Janssen, PhD/MD/FP
study chair · Radboud University Medical Centre Nijmegen
Sylvie H Lo Fo Wong, MD/FP
principal investigator · Radboud University Medical Centre, Nijmegen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion